Format

Send to

Choose Destination
Curr Urol Rep. 2017 Jul;18(7):50. doi: 10.1007/s11934-017-0698-3.

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Author information

1
Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA.
2
Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA. sliauw@radonc.uchicago.edu.

Abstract

PURPOSE OF REVIEW:

Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician.

RECENT FINDINGS:

The benefit of ADT on biochemical control is maintained with dose-escalated RT according to recently reported phase III studies. Furthermore, there is now prospective, randomized evidence to support the addition of ADT to RT in the post-prostatectomy setting. ADT continues to play an important role for prostate cancer patients receiving dose-escalated RT. Future research is needed to identify subgroups most likely to benefit from this combination.

KEYWORDS:

Hormonal therapy; Prostate cancer; Radiation therapy

PMID:
28589396
DOI:
10.1007/s11934-017-0698-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center